

# Yi Lin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3140714/publications.pdf>

Version: 2024-02-01

233  
papers

17,205  
citations

47006

47  
h-index

16183

124  
g-index

235  
all docs

235  
docs citations

235  
times ranked

14040  
citing authors

#	ARTICLE	IF	CITATIONS
1	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	27.0	3,865
2	Chimeric antigen receptor T-cell therapy " assessment and management of toxicities. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 47-62.	27.6	1,659
3	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase "2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.	10.7	1,467
4	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 1726-1737.	27.0	1,130
5	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	27.0	1,129
6	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet</i> , The, 2021, 398, 314-324.	13.7	711
7	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2020, 38, 3119-3128.	1.6	481
8	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	3.0	440
9	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	1.4	249
10	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4898-4911.	5.2	238
11	Immunosuppressive CD14 <sup>+</sup> HLA-DR <sup>low</sup> monocytes in prostate cancer. <i>Prostate</i> , 2010, 70, 443-455.	2.3	233
12	Immunosuppressive CD14 <sup>+</sup> HLA-DR <sup>low</sup> monocytes in B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 872-881.	1.4	218
13	Systemic immune suppression in glioblastoma: the interplay between CD14 <sup>+</sup> HLA-DR <sup>lo/neg</sup> monocytes, tumor factors, and dexamethasone. <i>Neuro-Oncology</i> , 2010, 12, 631-644.	1.2	194
14	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4319-4324.	1.6	193
15	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018, 8, 59.	6.2	171
16	Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2023, 41, 1265-1274.	1.6	160
17	IAP antagonists induce anti-tumor immunity in multiple myeloma. <i>Nature Medicine</i> , 2016, 22, 1411-1420.	30.7	133
18	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132

#	ARTICLE	IF	CITATIONS
19	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	3.0	115
20	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nature Reviews Clinical Oncology, 2018, 15, 218-218.	27.6	114
21	Diagnosis and Management of Waldenström Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
22	A Method for Identification and Analysis of Non-Overlapping Myeloid Immunophenotypes in Humans. PLoS ONE, 2015, 10, e0121546.	2.5	100
23	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood, 2021, 138, 11-22.	1.4	90
24	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367.	2.4	81
25	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. Blood, 2018, 132, 91-91.	1.4	81
26	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. American Journal of Hematology, 2015, 90, 181-186.	4.1	76
27	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	4.1	76
28	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 908-917.	3.0	72
29	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.	4.1	71
30	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.8	71
31	Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy. Blood, 2017, 130, 740-740.	1.4	67
32	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249.	7.2	64
33	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	6.2	64
34	CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 22-25.	1.4	63
35	Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. Blood, 2020, 136, 25-26.	1.4	63
36	Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease. Advances in Hematology, 2011, 2011, 1-17.	1.0	59

#	ARTICLE	IF	CITATIONS
37	Immunosuppressive CD14 <sup>+</sup> HLA-DR <sup>lo/neg</sup> monocytes are elevated in pancreatic cancer and are primed by tumor-derived exosomes. <i>OncImmunity</i> , 2017, 6, e1252013.	4.6	59
38	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	3.0	59
39	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, 82.	6.2	59
40	Association of an increased frequency of CD14 <sup>+</sup> HLA-DR <sup>lo/neg</sup> monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). <i>British Journal of Haematology</i> , 2012, 156, 674-676.	2.5	58
41	Cell Damage in Light Chain Amyloidosis. <i>Journal of Biological Chemistry</i> , 2016, 291, 19813-19825.	3.4	58
42	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.	5.2	58
43	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016, 91, 585-589.	4.1	57
44	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	4.1	57
45	Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DR <sup>lo/neg</sup> Cells): The Gateway to Improved Responses. <i>Frontiers in Immunology</i> , 2014, 5, 147.	4.8	55
46	Safety and Accuracy of Percutaneous Image-Guided Core Biopsy of the Spleen. <i>American Journal of Roentgenology</i> , 2016, 206, 655-659.	2.2	54
47	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	1.4	54
48	Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy. <i>Blood</i> , 2019, 134, 927-927.	1.4	52
49	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e006588.	2.6	51
50	Immune monitoring using the predictive power of immune profiles. , 2013, 1, 7.		50
51	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , 2017, 129, 82-87.	1.4	50
52	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	2.5	49
53	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.	4.1	49
54	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. <i>Blood</i> , 2021, 137, 1832-1835.	1.4	48

#	ARTICLE	IF	CITATIONS
55	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. <i>Nature Communications</i> , 2020, 11, 5173.	12.8	46
56	Induction therapy preautologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016, 91, 984-988.	4.1	45
57	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.	3.8	45
58	Systemic Immunoglobulin Light Chain Amyloidosis Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1354-1361.	3.0	43
59	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2022, 36, 801-808.	7.2	43
60	Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium. <i>Blood</i> , 2019, 134, 763-763.	1.4	42
61	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017, 92, 50-55.	4.1	41
62	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	5.2	41
63	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	2.5	40
64	Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. <i>European Heart Journal</i> , 2022, 43, 1928-1940.	2.2	39
65	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 644-654.	0.4	38
66	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	6.2	38
67	Enhancing the ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020, 95, 310-315.	4.1	37
68	Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. <i>Blood</i> , 2019, 134, 245-245.	1.4	37
69	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019, 33, 527-531.	7.2	36
70	Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 4224-4233.	7.0	33
71	Impact of MYD88 <sup>L265P</sup> mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	4.1	33
72	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2014, 89, 1051-1054.	4.1	32

#	ARTICLE	IF	CITATIONS
73	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6581-6588.	7.0	32
74	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	3.0	32
75	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. <i>Journal of Critical Care</i> , 2020, 58, 58-64.	2.2	31
76	Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , 2016, 91, 473-475.	4.1	30
77	A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 21.	6.2	30
78	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018, 8, 125.	6.2	29
79	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020, 34, 1135-1143.	7.2	29
80	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	7.2	28
81	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
82	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 326-335.	0.4	27
83	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.6	27
84	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. <i>Oncolmmunology</i> , 2020, 9, 1744947.	4.6	26
85	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.7	25
86	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	2.5	25
87	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	4.1	25
88	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 13-16.	3.0	25
89	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	6.2	25
90	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	4.1	24

#	ARTICLE	IF	CITATIONS
91	Posttransplant autoimmune encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e497.	6.0	24
92	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.	7.2	22
93	Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7512-7512.	1.6	22
94	Implications of detecting serum monoclonal protein by MASSâ€fix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 380-385.	2.5	21
95	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 473-482.	1.2	20
96	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 888-891.	4.1	18
97	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 70.	6.2	18
98	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, 4.	6.2	18
99	Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. <i>Leukemia</i> , 2020, 34, 1383-1393.	7.2	17
100	Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies. <i>Kidney International Reports</i> , 2021, 6, 1416-1422.	0.8	17
101	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2015, 126, 834-834.	1.4	17
102	Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3003-3003.	1.6	17
103	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. <i>Journal of Hematology and Oncology</i> , 2022, 15, 36.	17.0	17
104	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	4.1	16
105	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 677-687.	3.0	16
106	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. <i>Journal of Internal Medicine</i> , 2017, 281, 611-619.	6.0	15
107	Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895.	2.5	15
108	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019, 94, 751-756.	4.1	15

#	ARTICLE	IF	CITATIONS
109	Brexucabtagene Autoleucl for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. <i>Blood</i> , 2021, 138, 744-744.	1.4	15
110	The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor <sup>T</sup>-cell therapy. <i>American Journal of Hematology</i> , 2021, 96, E399-E402.	4.1	14
111	Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life. <i>Blood</i> , 2019, 134, 794-794.	1.4	14
112	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*. <i>Critical Care Medicine</i> , 2022, 50, 81-92.	0.9	13
113	2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucl (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma. <i>Blood</i> , 2018, 132, 2967-2967.	1.4	13
114	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2022, 6, 2763-2772.	5.2	13
115	Axicabtagene Ciloleucl Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2361-2364.	3.0	12
116	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642.	4.1	12
117	Strategies for improving the reporting of human immunophenotypes by flow cytometry. , 2014, 2, 18.		11
118	Immune independent crosstalk between lymphoma and myeloid suppressor CD14 <sup>+</sup> HLA-DR <sup>low/neg</sup> monocytes mediates chemotherapy resistance. <i>OncImmunology</i> , 2015, 4, e996470.	4.6	10
119	Danhong Promotes Angiogenesis in Diabetic Mice after Critical Limb Ischemia by Activation of CSE-H <sub>2</sub> S-VEGF Axis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-8.	1.2	9
120	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109.	3.5	9
121	Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage. <i>Cytotherapy</i> , 2017, 19, 1426-1437.	0.7	9
122	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	3.0	9
123	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2.	0.4	9
124	The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucl. <i>Blood Cancer Journal</i> , 2021, 11, 124.	6.2	9
125	Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucl in the Phase 1b/2 CARTITUDE-1 Study. <i>Blood</i> , 2020, 136, 45-46.	1.4	9
126	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. <i>Blood</i> , 2013, 122, 2151-2151.	1.4	9



#	ARTICLE	IF	CITATIONS
127	Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 171-187.	3.0	9
128	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018, 32, 1421-1426.	7.2	8
129	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 53-56.	0.4	8
130	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. <i>Hematological Oncology</i> , 2021, 39, 658-663.	1.7	8
131	Comparison of the current renal staging, progression and response criteria to predict renal survival in <sc>AL</sc> amyloidosis using a <sc>Mayo</sc> cohort. <i>American Journal of Hematology</i> , 2021, 96, 446-454.	4.1	8
132	A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 4095-4095.	1.4	8
133	Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel). <i>Blood</i> , 2020, 136, 40-42.	1.4	8
134	Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 41-42.	1.4	8
135	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. <i>Blood</i> , 2015, 126, 3050-3050.	1.4	8
136	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2016, 128, 4392-4392.	1.4	8
137	Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7554-7554.	1.6	7
138	Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R) Tj ETQq0 0 0.rgBT /Overlock 10 T		
139	Age defining immune effector cell associated neurotoxicity syndromes in aggressive large <sc>B</sc> cell lymphoma patients treated with axicabtagene ciloleucel. <i>American Journal of Hematology</i> , 2021, 96, E427-E430.	4.1	7
140	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. <i>Blood</i> , 2012, 120, 3972-3972.	1.4	7
141	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. <i>Blood</i> , 2019, 134, 4106-4106.	1.4	6
142	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015, 126, 1774-1774.	1.4	6
143	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, , .	4.1	6
144	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	6.2	6

#	ARTICLE	IF	CITATIONS
145	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.	4.1	5
146	Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7552-7552.	1.6	5
147	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4197-4197.	1.4	5
148	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2022, 97, 209-215.	4.1	5
149	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. <i>American Journal of Hematology</i> , 2022, , .	4.1	5
150	Meta-analysis of ciltacabtagene autoleucel versus physicianâ€™s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. <i>Current Medical Research and Opinion</i> , 2022, 38, 1759-1767.	1.9	5
151	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41.	3.0	4
152	Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020, 95, E60-E62.	4.1	4
153	Outcomes in mantle cell lymphoma with central nervous system involvement.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19527-e19527.	1.6	4
154	Lines of therapy before autologous stem cell transplant and <scp>CARâ€T</scp> affect outcomes in aggressive <scp>Nonâ€Hodgkin's</scp> lymphoma. <i>American Journal of Hematology</i> , 2021, 96, E386-E389.	4.1	4
155	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 30-31.	1.4	4
156	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	1.4	4
157	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 1363-1368.	1.3	4
158	Serum free light chain measurements to reduce 24â€h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018, 93, 1207-1210.	4.1	3
159	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 95.	6.2	3
160	Impact of hypoalbuminemia on the prognosis of relapsed/refractory Bâ€cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	2.2	3
161	Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8036-8036.	1.6	3
162	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 12-13.	1.4	3

#	ARTICLE	IF	CITATIONS
163	Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2020, 136, 29-30.	1.4	3
164	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	1.4	3
165	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	1.3	2
166	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19547-e19547.	1.6	2
167	Characteristics, outcomes, and risk factors of ICANS after axicabtagene ciloleucel: Does age matter?. <i>Journal of Clinical Oncology</i> , 2021, 39, e19556-e19556.	1.6	2
168	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	1.4	2
169	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 4386-4386.	1.4	2
170	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.	1.4	2
171	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 3117-3117.	1.4	2
172	Systemic misfolding of immunoglobulins in the test tube and in the cell. <i>FASEB Journal</i> , 2018, 32, 247.3.	0.5	2
173	Depth of Response in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 4141-4141.	1.4	2
174	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5293-5293.	1.4	2
175	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2022, , .	4.1	2
176	Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity.. <i>Journal of Clinical Oncology</i> , 2022, 40, 190-190.	1.6	2
177	Peak absolute lymphocyte count after <sc>CAR</sc> infusion predicts clinical response in aggressive lymphoma. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	2
178	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 44-45.	3.0	1
179	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7542-7542.	1.6	1
180	Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7555-7555.	1.6	1

#	ARTICLE	IF	CITATIONS
181	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019, 134, 4334-4334.	1.4	1
182	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020, 136, 7-8.	1.4	1
183	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , 2012, 120, 946-946.	1.4	1
184	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2013, 122, 3095-3095.	1.4	1
185	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 3992-3992.	1.4	1
186	Trends in survival of patients with primary plasma cell leukemia: A population-based analysis from 1973 to 2010.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8608-8608.	1.6	1
187	Novel Mutations in NOTCH and Altered Wnt/ $\beta$ -Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4103-4103.	1.4	1
188	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 622-622.	1.4	1
189	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	1.4	1
190	Patient-Reported Outcome Driven Case Management System for Hematology " a Prospective Study. <i>Blood</i> , 2018, 132, 719-719.	1.4	1
191	Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel). <i>Blood</i> , 2019, 134, 5343-5343.	1.4	1
192	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019, 134, 1800-1800.	1.4	1
193	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019, 134, 5490-5490.	1.4	1
194	Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 30-30.	1.4	1
195	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020, 136, 31-32.	1.4	1
196	Preventive Effects of Epinephrine for Critically Ill Patients? More Questions Waiting to Be Answered. <i>Digestive Diseases and Sciences</i> , 2019, 64, 283-284.	2.3	0
197	Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7558-7558.	1.6	0
198	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20016-e20016.	1.6	0

#	ARTICLE	IF	CITATIONS
199	The impact of body weight and body mass index on outcomes of diffuse large B-cell lymphoma treated with axicabtagene ciloleucel.. Journal of Clinical Oncology, 2021, 39, e19554-e19554.	1.6	0
200	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. Blood, 2012, 120, 448-448.	1.4	0
201	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2012, 120, 1988-1988.	1.4	0
202	Implications of rapidity of response to initial therapy in multiple myeloma.. Journal of Clinical Oncology, 2013, 31, 8606-8606.	1.6	0
203	Definition of a high-risk population among patients with AL amyloidosis not undergoing autologous stem cell transplantation using bone marrow plasmacytosis and the presence of CRAB.. Journal of Clinical Oncology, 2013, 31, 8516-8516.	1.6	0
204	Continued monoclonal protein response beyond day 100 after auto-transplantation for multiple myeloma.. Journal of Clinical Oncology, 2013, 31, 8587-8587.	1.6	0
205	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. Blood, 2013, 122, 1979-1979.	1.4	0
206	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3209-3209.	1.4	0
207	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. Blood, 2013, 122, 1774-1774.	1.4	0
208	Presence and function of CD14+CD16-HLADR <sup>low</sup> monocytes in the peripheral blood of patients with T <sub>H</sub> -cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2014, 32, e19539-e19539.	1.6	0
209	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). Blood, 2015, 126, 3292-3292.	1.4	0
210	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. Blood, 2015, 126, 3039-3039.	1.4	0
211	AL Amyloidosis and Patient Reported Quality of Life. Blood, 2015, 126, 3317-3317.	1.4	0
212	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. Blood, 2016, 128, 3273-3273.	1.4	0
213	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.	1.4	0
214	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. Blood, 2016, 128, 3306-3306.	1.4	0
215	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. Blood, 2016, 128, 1194-1194.	1.4	0
216	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. Blood, 2016, 128, 3269-3269.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Outcome of Very Young (â‰‰ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016, 128, 5576-5576.	1.4	0
218	Comparative Analysis of Staging Systems in AL Amyloidosis. <i>Blood</i> , 2018, 132, 3228-3228.	1.4	0
219	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. <i>Blood</i> , 2018, 132, 4449-4449.	1.4	0
220	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. <i>Blood</i> , 2018, 132, 3226-3226.	1.4	0
221	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. <i>Blood</i> , 2018, 132, 3227-3227.	1.4	0
222	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4615-4615.	1.4	0
223	WaldenstrÅm Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	1.4	0
224	Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy. <i>Blood</i> , 2019, 134, 5352-5352.	1.4	0
225	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 5833-5833.	1.4	0
226	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2020, 136, 27-28.	1.4	0
227	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
228	The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucel. <i>Blood</i> , 2020, 136, 23-25.	1.4	0
229	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020, 136, 44-45.	1.4	0
230	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
231	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
232	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 21-22.	1.4	0
233	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 2022, , OP2100789.	2.9	0